The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Abstract
OBJECTIVES: Amyloid-beta(42) (Abeta(42)) appears central to Alzheimer's disease (AD) pathogenesis and is a major component of amyloid plaques. Mean cerebrospinal fluid (CSF) Abeta(42) is decreased in dementia of the Alzheimer's type. This decrease may reflect plaques acting as an Abeta(42) "sink," hindering transport of soluble Abeta(42) between brain and CSF. We investigated this hypothesis. METHODS: We compared the in vivo brain amyloid load (via positron emission tomography imaging of the amyloid-binding agent, Pittsburgh Compound-B [PIB]) with CSF Abeta(42) and other measures (via enzyme-linked immunosorbent assay) in clinically characterized research subjects. RESULTS: Subjects fell into two nonoverlapping groups: those with positive PIB binding had the lowest CSF Abeta(42) level, and those with negative PIB binding had the highest CSF Abeta(42) level. No relation was observed between PIB binding and CSF Abeta(40), tau, phospho-tau(181), plasma Abeta(40), or plasma Abeta(42). Importantly, PIB binding and CSF Abeta(42) did not consistently correspond with clinical diagnosis; three cognitively normal subjects were PIB-positive with low CSF Abeta(42), suggesting the presence of amyloid in the absence of cognitive impairment (ie, preclinical AD). INTERPRETATION: These observations suggest that brain amyloid deposition results in low CSF Abeta(42), and that amyloid imaging and CSF Abeta(42) may potentially serve as antecedent biomarkers of (preclinical) AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The continuous relationship between CSF Aβ42 and amyloid PET, however, is “L-shaped” rather than linear [116,117,120].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [120]
In the citing paper
“A preponderance of evidence supports the interpretation that PIB uptake and CSF Aβ42 are reliable surrogate markers of amyloid plaque pathology in living subjects (15-19).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [18]
In the citing paper
“Since people with brain amyloid deposition have low CSF Aβ42 (Fagan et al., 2006), this strongly suggests that amyloid deposition on average is beginning earlier in apoE4-positive subjects.”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Fagan et al., 2006
In the citing paper
“Since people with brain amyloid deposition have low CSF Aβ42 (Fagan et al., 2006), this strongly suggests that amyloid deposition on average is beginning earlier in apoE4-positive subjects.”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Fagan et al., 2006
In the citing paper
“Antemortem diagnosis also relies heavily on the presence of Aβ and tau, either as measured in the spinal fluid or imaged using positron emission tomography (PET) [7–10].”
From Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau (2021) · cites this paper as [9]
In the citing paper
“Levels of CSF Aβ42 are typically reduced in dementia of the Alzheimer type (DAT),8-11 reflecting its aggregation and deposition as amyloid in the brain,12”
From Decreased cerebrospinal fluid Aβ 42 correlates with brain atrophy in cognitively normal elderly (2009) · cites this paper as [12]
Citations
Cites
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Self-citationProfound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease
Gómez-Isla, T., Price, J. L., McKeel Jr., D. W., Morris, J. C., Growdon, J. H., & Hyman, B. T. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-14-04491.1996 · Cited by 1,796 · cited 1×
“icant neuronal loss in vulnerable regions, such as the entorhinal cortex.(19) However, cognitively normal individuals with neuropathological AD (preclinical AD) do not demonstrate such neuronal loss,(20) and we observed reduced CSF A 42 levels in three cognitively normal subjects.”
BackgroundSelf-citationKawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00372.2001 · Cited by 1,053
Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656
Morris, J. C., & Price, J. L. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:101 · Cited by 513
Self-citationCirrito, J. R., May, P. C., O'Dell, M. A., Taylor, J. W., Parsadanian, M., Cramer, J. W., Audia, J. E., Nissen, J. S., Bales, K. R., Paul, S. M., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08844.2003 · Cited by 394
Self-citationValidation of clinical diagnostic criteria for Alzheimer's disease
Morris, J. C., McKeel, D. W., Fulling, K., Torack, R. M., & Berg, L. (1988) · Annals of Neurology · doi:10.1002/ana.410240105 · Cited by 362
Self-citationHULETTE, C. M., WELSH-BOHMER, K. A., MURRAY, M. G., SAUNDERS, A. M., MASH, D. C., & MCINTYRE, L. M. (1998) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199812000-00009 · Cited by 311
Research works printed but not linked: 21
- 10.1016/S0925-4439(00)00031-4 · DOI
- 10.1001/archneur.55.3.326 · DOI · Paper page
- 10.1001/archneur.58.3.397 · DOI
- 10.1002/ana.20009 · DOI · Paper page
- 10.1002/1531-8249(200008)48:2<201::AID-ANA10>3.0.CO;2-X · DOI
- 10.1021/jm030026b · DOI
- 10.1016/B978-012389760-2/50028-1 · DOI
- 10.1097/00004647-199609000-00008 · DOI
- 10.1038/sj.jcbfm.9600146 · DOI
- Price J, 2005, PIB PET amyloid imaging in Alzheimer's disease and mild cognitive impairment, J Nucl Med, 46, 123P
- 10.1001/archneur.58.11.1803 · DOI
- 10.1046/j.1471-4159.2002.00889.x · DOI
- 10.1001/archneur.58.9.1395 · DOI · Paper page
- 10.1111/j.1532-5415.2004.52459.x · DOI
- 10.1126/science.1067568 · DOI · Paper page
- 10.1002/1531-8249(199909)46:3<412::AID-ANA19>3.0.CO;2-A · DOI
- 10.1212/01.WNL.0000091890.32140.8F · DOI · Paper page
- 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X · DOI
- 10.1212/WNL.59.7.1034 · DOI
- 10.1212/01.wnl.0000172919.50001.d6 · DOI
- 10.1172/JCI200317527 · DOI
Cited by
Sorted by citations
Items 101–156 of 156
Spellman, D. S., Wildsmith, K. R., Honigberg, L. A., Tuefferd, M., Baker, D., Raghavan, N., Nairn, A. C., Croteau, P., Schirm, M., Allard, R., et al. (2015) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201400178 · Cited by 161
Wolk, D. A. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.153 · Cited by 156
Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149
Wennström, M., Surova, Y., Hall, S., Nilsson, C., Minthon, L., Boström, F., Hansson, O., & Nielsen, H. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053250 · Cited by 141
Kauwe, J. S. K., Bailey, M. H., Ridge, P. G., Perry, R., Wadsworth, M. E., Hoyt, K. L., Staley, L. A., Karch, C. M., Harari, O., Cruchaga, C., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004758 · Cited by 125
Self-citationWhen Does Alzheimer′s Disease Really Start? The Role of Biomarkers
Lloret, A., Esteve, D., Lloret, M.-A., Cervera-Ferri, A., Lopez, B., Nepomuceno, M., & Monllor, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225536 · Cited by 131
Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years
Albert, M., Zhu, Y., Moghekar, A., Mori, S., Miller, M. I., Soldan, A., Pettigrew, C., Selnes, O., Li, S., & Wang, M.-C. (2018) · Brain · doi:10.1093/brain/awx365 · Cited by 118
Cruchaga, C., Kauwe, J. S. K., Mayo, K., Spiegel, N., Bertelsen, S., Nowotny, P., Shah, A. R., Abraham, R., Hollingworth, P., Harold, D., et al. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001101 · Cited by 128
Self-citationSystems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau
Rayaprolu, S., Higginbotham, L., Bagchi, P., Watson, C. M., Zhang, T., Levey, A. I., Rangaraju, S., & Seyfried, N. T. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00840-3 · Cited by 118
Identifying incipient dementia individuals using machine learning and amyloid imaging
Mathotaarachchi, S., Pascoal, T. A., Shin, M., Benedet, A. L., Kang, M. S., Beaudry, T., Fonov, V. S., Gauthier, S., & Rosa-Neto, P. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.06.027 · Cited by 118
Disease modifying therapy for AD?1
Golde, T. E. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04211.x · Cited by 117
Aβ-amyloid and Tau Imaging in Dementia
Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.006 · Cited by 110
Sex-specific genetic predictors of Alzheimer’s disease biomarkers
(ADNI), A. D. N. I., Deming, Y., The Alzheimer Disease Genetics Consortium (ADGC), Dumitrescu, L., Barnes, L. L., Thambisetty, M., Kunkle, B., Gifford, K. A., Bush, W. S., Chibnik, L. B., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1881-4 · Cited by 110
Toward the Treatment and Prevention of Alzheimer's Disease: Rational Strategies and Recent Progress
Gandy, S., & DeKosky, S. T. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-092611-084441 · Cited by 110
Self-citationImaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease
Vlassenko, A. G., McCue, L., Jasielec, M. S., Su, Y., Gordon, B. A., Xiong, C., Holtzman, D. M., Benzinger, T. L. S., Morris, J. C., & Fagan, A. M. (2016) · Annals of Neurology · doi:10.1002/ana.24719 · Cited by 106
Self-citationGordon, B. A., Blazey, T., Su, Y., Fagan, A. M., Holtzman, D. M., Morris, J. C., & Benzinger, T. L. S. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2642 · Cited by 105
Self-citationAnti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy
Yanamandra, K., Patel, T. K., Jiang, H., Schindler, S., Ulrich, J. D., Boxer, A. L., Miller, B. L., Kerwin, D. R., Gallardo, G., Stewart, F., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal2029 · Cited by 100
Self-citationAmyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease
Vandenberghe, R., Adamczuk, K., Dupont, P., Laere, K. V., & Chételat, G. (2013) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.03.014 · Cited by 99
“11C-PIB retention values correlate with Enzyme Linked ImmunoSorbent Assay (ELISA) measurements of Aβ42 more so than Aβ40 (Ikonomovic et al., 2012).”
BackgroundIrwin, D. J., Trojanowski, J. Q., & Grossman, M. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00006 · Cited by 96
Weigand, S. D., Vemuri, P., Wiste, H. J., Senjem, M. L., Pankratz, V. S., Aisen, P. S., Weiner, M. W., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.08.230 · Cited by 93
GPS driving: a digital biomarker for preclinical Alzheimer disease
Bayat, S., Babulal, G. M., Schindler, S. E., Fagan, A. M., Morris, J. C., Mihailidis, A., & Roe, C. M. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00852-1 · Cited by 91
Self-citationBiomarkers in Neurodegenerative Diseases
Jeromin, A., & Bowser, R. (2017) · Advances in Neurobiology · doi:10.1007/978-3-319-57193-5_20 · Cited by 92
Bendlin, B. B., Carlsson, C. M., Johnson, S. C., Zetterberg, H., Blennow, K., Willette, A. A., Okonkwo, O. C., Sodhi, A., Ries, M. L., Birdsill, A. C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037720 · Cited by 91
Targeting Aβ and tau in Alzheimer's disease, an early interim report
Golde, T. E., Petrucelli, L., & Lewis, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.035 · Cited by 89
Quantitative structural MRI for early detection of Alzheimer's disease
McEvoy, L. K., & Brewer, J. B. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.162 · Cited by 90
Harari, O., Cruchaga, C., Kauwe, J. S. K., Ainscough, B. J., Bales, K., Pickering, E. H., Bertelsen, S., Fagan, A. M., Holtzman, D. M., Morris, J. C., et al. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.11.032 · Cited by 82
Self-citationMaternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes
Mosconi, L., Berti, V., Swerdlow, R. H., Pupi, A., Duara, R., & de Leon, M. (2010) · Human Genomics · doi:10.1186/1479-7364-4-3-170 · Cited by 85
Kauwe, J. S. K., Jacquart, S., Chakraverty, S., Wang, J., Mayo, K., Fagan, A. M., Holtzman, D. M., Morris, J. C., & Goate, A. M. (2007) · Annals of Neurology · doi:10.1002/ana.21099 · Cited by 84
ADGC, A. D. N. I., Chapuis, J., Flaig, A., Grenier-Boley, B., Eysert, F., Pottiez, V., Deloison, G., Vandeputte, A., Ayral, A.-M., Mendes, T., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1652-z · Cited by 75
Alzheimer’s disease risk variants show association with cerebrospinal fluid amyloid beta
Kauwe, J. S. K., Wang, J., Mayo, K., Morris, J. C., Fagan, A. M., Holtzman, D. M., & Goate, A. M. (2009) · neurogenetics · doi:10.1007/s10048-008-0150-4 · Cited by 82
Self-citationA potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin
Deming, Y., Xia, J., Cai, Y., Lord, J., Holmans, P., Bertelsen, S., Holtzman, D., Morris, J. C., Bales, K., Pickering, E. H., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.09.009 · Cited by 66
“The Knight ADRC Biomarker Core and ADNI measured CSF Ab42, tau, and phosphotau (ptau181) levels as described previously (Fagan et al., 2006; Shaw et al., 2009).”
MethodSelf-citationApolipoprotein E Genotype Affects Size of ApoE Complexes in Cerebrospinal Fluid
Heinsinger, N. M., Gachechiladze, M. A., & Rebeck, G. W. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw067 · Cited by 74
Elias-Sonnenschein, L. S., Helisalmi, S., Natunen, T., Hall, A., Paajanen, T., Herukka, S.-K., Laitinen, M., Remes, A. M., Koivisto, A. M., Mattila, K. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059676 · Cited by 70
Early diagnosis of Alzheimer's disease from elevated olfactory mucosal miR-206 level.
Moon, J., Lee, S.-T., Kong, I. G., Byun, J.-I., Sunwoo, J.-S., Shin, J.-W., Shim, J.-Y., Park, J.-H., Jeon, D., Jung, K.-H., et al. (2016) · Scientific Reports · doi:10.1038/srep20364 · Cited by 69
Self-citationChallenges associated with biomarker‐based classification systems for Alzheimer's disease
Illán‐Gala, I., Pegueroles, J., Montal, V., Vilaplana, E., Carmona‐Iragui, M., Alcolea, D., Dickerson, B. C., Sánchez‐Valle, R., de Leon, M. J., Blesa, R., et al. (2018) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.03.004 · Cited by 62
The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease
for the Dominantly Inherited Alzheimer Network (DIAN), Twohig, D., Rodriguez-Vieitez, E., Sando, S. B., Berge, G., Lauridsen, C., Møller, I., Grøntvedt, G. R., Bråthen, G., Patra, K., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0624-z · Cited by 68
Self-citationRoussotte, F. F., Gutman, B. A., Madsen, S. K., Colby, J. B., Thompson, P. M., & Initiative, F. T. A. D. N. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.5236-13.2014 · Cited by 63
Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease
Alexopoulos, P., Kriett, L., Haller, B., Klupp, E., Gray, K., Grimmer, T., Laskaris, N., Förster, S., Perneczky, R., Kurz, A., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.03.006 · Cited by 62
Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer’s disease
Ewers, M., Cheng, X., Zhong, Z., Nural, H. F., Walsh, C., Meindl, T., Teipel, S. J., Buerger, K., He, P., Shen, Y., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-091153 · Cited by 58
Role of Family History for Alzheimer Biomarker Abnormalities in the Adult Children Study
Xiong, C. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.208 · Cited by 56
Boerwinkle, A. H., Gordon, B. A., Wisch, J., Flores, S., Henson, R. L., Butt, O. H., McKay, N., Chen, C. D., Benzinger, T. L. S., Fagan, A. M., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00408-2 · Cited by 55
Self-citationLongitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study
Xiong, C., Jasielec, M. S., Weng, H., Fagan, A. M., Benzinger, T. L. S., Head, D., Hassenstab, J., Grant, E., Sutphen, C. L., Buckles, V., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002593 · Cited by 54
Self-citationQuantum Dots as A Theranostic Approach in Alzheimer’s Disease: A Systematic Review
Villalva, M. D., Agarwal, V., Ulanova, M., Sachdev, P. S., & Braidy, N. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0104 · Cited by 53
Clinical, biological, and imaging features of monogenic Alzheimer’s disease
Pilotto, A., Padovani, A., & Borroni, B. (2013) · BioMed Research International · doi:10.1155/2013/689591 · Cited by 47
CSF Aβ42, Tau and Phosphorylated Tau Correlate with Medial Temporal Lobe Atrophy
Herukka, S.-K., Pennanen, C., Soininen, H., & Pirttilä, T. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-14105 · Cited by 47
Sheline, Y. I., Snider, B. J., Beer, J. C., Seok, D., Fagan, A. M., Suckow, R. F., Lee, J.-M., Waligorska, T., Korecka, M., Aselcioglu, I., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010725 · Cited by 45
Self-citationMormino, E. C. (2014) · Neuropsychology Review · doi:10.1007/s11065-014-9267-4 · Cited by 44
Amyloid‐β induces sleep fragmentation that is rescued by fatty acid binding proteins in Drosophila
Gerstner, J. R., Lenz, O., Vanderheyden, W. M., Chan, M. T., Pfeiffenberger, C., & Pack, A. I. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.23778 · Cited by 40
Tang, W., Huang, Q., Wang, Y., Wang, Z.-Y., & Yao, Y.-Y. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.07.015 · Cited by 38
Carandini, T., Arighi, A., Sacchi, L., Fumagalli, G. G., Pietroboni, A. M., Ghezzi, L., Colombi, A., Scarioni, M., Fenoglio, C., De Riz, M. A., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0543-7 · Cited by 36
Olive, C., Ibanez, L., Farias, F. H. G., Wang, F., Budde, J. P., Norton, J. B., Gentsch, J., Morris, J. C., Li, Z., Dube, U., et al. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-200019 · Cited by 32
Self-citationProgress Update: Fluid and Imaging Biomarkers in Alzheimer’s Disease
Sutphen, C. L., Fagan, A. M., & Holtzman, D. M. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.07.031 · Cited by 31
Self-citationAlzheimer's disease biomarkers: correspondence between human studies and animal models
Sabbagh, J. J., Kinney, J. W., & Cummings, J. L. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.04.010 · Cited by 27
Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease—From Brain Starch to Bench and Bedside
Pawlowski, M., Meuth, S., & Duning, T. (2017) · Diagnostics · doi:10.3390/diagnostics7030042 · Cited by 25
Ramos de Matos, M., Ferreira, C., Herukka, S.-K., Soininen, H., Janeiro, A., Santana, I., Baldeiras, I., Almeida, M. R., Lleó, A., Dols-Icardo, O., et al. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180512 · Cited by 18
Proteomic clusters underlie heterogeneity in preclinical Alzheimer’s disease progression
Wisch, J. K., Butt, O. H., Gordon, B. A., Schindler, S. E., Fagan, A. M., Henson, R. L., Yang, C., Boerwinkle, A. H., Benzinger, T. L. S., Holtzman, D. M., et al. (2023) · Brain · doi:10.1093/brain/awac484 · Cited by 11
Self-citation
Metadata
- Authors
- Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., DeKosky, S. T., Morris, J. C., & Holtzman, D. M.
- Affiliations
- Washington University in St. Louis (US)
- University of Pittsburgh (US)
- Corresponding author
- Fagan, Anne M.
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2006-02-17
- Volume
- 59
- Issue
- 3
- Pages
- 512-519
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2006858320
- Cited by
- 1,246
- References
- 8
- Citations by year
- 2026: 16 · 2025: 30 · 2024: 37 · 2023: 35 · 2022: 40 · 2021: 45 · 2020: 77 · 2019: 56 · 2018: 50 · 2017: 67 · 2016: 71 · 2015: 69 · 2014: 65 · 2013: 94 · 2012: 76
- FWCI
- 27.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (AG03991, AG 05681, AG026276, P50AG005681, P01AG003991, P01AG026276)
- National Institute of Neurological Disorders and Stroke (P30NS048056)
- National Center for Research Resources (M01-RR00036, M01RR000036)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- amyloid-beta 42, cerebrospinal fluid biomarkers, Pittsburgh compound B, amyloid plaques, Alzheimer's disease, preclinical Alzheimer's disease, amyloid imaging, tau protein, phosphorylated tau, plasma amyloid-beta, cognitive impairment
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Diagnostic Imaging, Female, Humans, Image Processing, Computer-Assisted, Male, Memory, Middle Aged, Neuropsychological Tests, Peptide Fragments, Tissue Distribution, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
